Natera, Inc. (NASDAQ:NTRA) Given Average Rating of “Buy” by Analysts

Natera, Inc. (NASDAQ:NTRA) has been assigned a consensus rating of “Buy” from the sixteen ratings firms that are presently covering the firm, MarketBeat.com reports. Sixteen analysts have rated the stock with a buy recommendation. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $170.94.

Several equities research analysts recently commented on the stock. Barclays started coverage on shares of Natera in a research report on Thursday, January 23rd. They issued an “overweight” rating and a $200.00 price target for the company. StockNews.com lowered Natera from a “hold” rating to a “sell” rating in a report on Thursday, November 14th. Piper Sandler lifted their price target on Natera from $150.00 to $200.00 and gave the company an “overweight” rating in a report on Monday, November 18th. Morgan Stanley increased their price objective on Natera from $132.00 to $176.00 and gave the stock an “overweight” rating in a research note on Thursday, November 14th. Finally, TD Cowen lifted their target price on Natera from $155.00 to $175.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th.

Insider Buying and Selling

In other news, CFO Michael Burkes Brophy sold 43,502 shares of Natera stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $176.88, for a total value of $7,694,633.76. Following the transaction, the chief financial officer now owns 70,629 shares of the company’s stock, valued at $12,492,857.52. This trade represents a 38.12 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider John Fesko sold 663 shares of the company’s stock in a transaction on Thursday, February 6th. The stock was sold at an average price of $177.77, for a total transaction of $117,861.51. Following the sale, the insider now directly owns 156,044 shares of the company’s stock, valued at approximately $27,739,941.88. This represents a 0.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 295,772 shares of company stock worth $49,741,699. Corporate insiders own 7.60% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Creative Planning increased its stake in shares of Natera by 18.3% in the third quarter. Creative Planning now owns 5,833 shares of the medical research company’s stock worth $740,000 after purchasing an additional 904 shares during the period. Moss Adams Wealth Advisors LLC increased its position in Natera by 5.4% in the 3rd quarter. Moss Adams Wealth Advisors LLC now owns 2,646 shares of the medical research company’s stock worth $336,000 after buying an additional 135 shares during the period. Allspring Global Investments Holdings LLC lifted its holdings in shares of Natera by 25.0% during the third quarter. Allspring Global Investments Holdings LLC now owns 1,229,558 shares of the medical research company’s stock worth $156,092,000 after buying an additional 246,246 shares during the last quarter. Private Advisor Group LLC boosted its position in shares of Natera by 5.2% in the third quarter. Private Advisor Group LLC now owns 2,721 shares of the medical research company’s stock valued at $346,000 after acquiring an additional 135 shares during the period. Finally, Lecap Asset Management Ltd. grew its stake in shares of Natera by 8.2% in the third quarter. Lecap Asset Management Ltd. now owns 7,003 shares of the medical research company’s stock worth $889,000 after acquiring an additional 531 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Price Performance

NTRA stock opened at $162.31 on Monday. Natera has a one year low of $69.74 and a one year high of $183.00. The firm has a 50-day moving average of $167.98 and a two-hundred day moving average of $145.23. The firm has a market capitalization of $21.43 billion, a PE ratio of -92.22 and a beta of 1.66. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.